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Abstract: Clinical observations have revealed a strong correlation between loss of bone density 
in HIV-infected individuals, particularly in conjunction with the antiretroviral drug tenofovir, 
a nucleotide analog that inhibits HIV reverse transcriptase. The most compelling correlations 
have been observed in clinical studies involving young children and adolescents. These obser-
vations strongly suggest that bone density is being affected during active bone growth and 
development, implicating a role for tenofovir in bone loss. Here we discuss the literature and 
potential mechanisms for how tenofovir-associated bone loss may arise, which likely involves 
perturbation of cellular DNA synthesis and gene expression. Elucidation of the mechanism(s) 
involved in tenofovir-mediated bone loss will help in developing adjuvant therapies to reduce 
tenofovir-associated bone density loss.
Keywords: tenofovir, osteoblast, osteoclast, dysfunction, PMPA, renal
Introduction
Nucleoside reverse transcriptase inhibitors (NRTIs) represent the backbone of highly 
active antiretroviral therapy (HAART) for the clinical management of human immuno-
deficiency virus (HIV) infection. NRTIs target HIV reverse transcriptase and prevent 
the synthesis of viral DNA. NRTIs lack a 3′-hydroxyl group on the deoxyribose and 
following incorporation of the next incoming deoxynucleotide cannot form the new 
5′-3′ phosphodiester bond required to extend the synthesis of the DNA chain. Thus, 
NRTIs act as chain terminators of HIV DNA synthesis. Due to the development of HIV 
drug resistance, there has been a continual need for the discovery and development of 
new drug targets and new anti-HIV drugs.
Tenofovir, also called 9-(R)-{2-(phosphonomethoxy)propyl}adenine or PMPA, 
is a nucleotide analog (Figure 1) and was approved in 2001 for use in treating HIV 
infection and more recently for chronic hepatitis B infection.1 The prodrug form is 
tenofovir disoproxil fumarate (TDF) (Figure 1). Tenofovir has improved potency as 
it is a nucleotide and has an abbreviated intracellular activation pathway to allow a 
more rapid and complete conversion to the active drug. The prodrug TDF has a labile 
lipophilic group to facilitate penetration through target cell membranes. Tenofovir 
is not known to be a substrate, inducer or inhibitor of human cytochrome P450 
enzymes in vitro or in vivo. Tenofovir has high potency and an unusually durable 
response when used in trials of single-agent therapy intensification in highly treatment-
experienced individuals.2 The active metabolite, tenofovir diphosphate, exhibits a 
long intracellular half-life in both resting and activated peripheral blood mononuclear 
cells, which allows for single daily dosing. The clinical efficacy of TDF has been Therapeutics and Clinical Risk Management 2010:6 42
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shown in Phase II (ie, GS-98-902) and III (ie, GS-99-907) 
clinical trials, with highly treatment-experienced patients.3,4 
The Phase II and III studies were both randomized, double-
blind, placebo-controlled, multicenter intensification studies 
of TDF that confirmed the utility of TDF in which patients 
added TDF therapy (300 mg once daily) in addition to their 
existing regimen.5
While there has been great success in the use of tenofovir 
in treating HIV infection, there have been clinical reports of 
tenofovir-associated side effects. Among those side effects, 
multiple studies have implicated tenofovir-associated bone 
loss. This review discusses the literature on tenofovir-
associated bone loss and presents several plausible mecha-
nisms that might explain the basis for bone loss.
Tenofovir-associated bone loss
Bone is a dynamic tissue that is formed and maintained by 
osteoblasts (which form bone) and osteoclasts (which resorb 
bone). An extensive cell signaling network between osteo-
blasts and osteoclasts is required for maintaining a balance 
in the activities of these two cell types in bone remodeling 
and bone health. Recent studies have indicated that direct 
signals between bone cells are important for regulating 
bone remodeling.6–8 For example, it has been shown that 
osteoclasts can initiate bone formation via signaling to 
osteoblasts independent of their ability to resorb bone.9,10 
In patients with autosomal dominant osteopetrosis type II it 
was demonstrated that the number of osteoclasts but not their 
activity controls bone formation.11 Conversely, osteoblasts 
regulate osteoclast differentiation by expressing two factors 
that are necessary and sufficient for osteoclast formation: 
M-CSF12 and RANKL13; M-CSF is required for survival and 
proliferation of early osteoclast precursors.14–16 Binding of 
RANKL, produced by osteoblasts, and the RANK receptor 
on osteoclasts stimulates expression of genes necessary for 
osteoclast differentiation, cellular fusion and bone resorption. 
Additionally, osteoblasts express osteoprotegerin, a soluble 
decoy receptor for RANKL, which inhibits activation of 
RANK by RANKL. The ratio of RANKL to osteoprotegerin 
produced by osteoblasts is a major determinant of osteoclast 
forming activity within the bone microenvironment and 
allows for close coordination between bone formation and 
bone resorption under normal physiological conditions.
Perturbations in the function of osteoblasts or osteoclasts 
can lead to bone loss, clinically presented as osteopenia or 
osteoporosis. Osteoporosis commonly occurs in women 
following menopause, where it is called postmenopausal 
osteoporosis, but can also occur in men or anyone with certain 
hormonal disorders, other chronic diseases, or due to medica-
tions such as glucocorticoids.17–23 Vitamin D deficiencies can 
result in bone softening, resulting in osteomalacia – in children 
called rickets.24–26 Loss of osteoclast function increases bone 
density, resulting in osteopetrosis. One example of a human 
condition involving osteopetrosis is a rare inherited disorder, 
called Albers–Schonberg disease. In osteopetrosis, osteoclast 
numbers may be lower, normal, or elevated, however the critical 
factor in the development of osteopetrosis is the dysfunction 
of osteoclasts. For example, a reduction of carbonic anhydrase 
expression in osteoclasts can result in defects in hydrogen ion 
pumping, which can cause a dysfunction in osteoclast resorp-
tion of bone.27,28 However, osteoblast dysfunction, particularly 
hyperactivity, can also result in osteopetrosis29,30 while a 
decrease in function can contribute to osteoporosis.
HIV infection has been implicated as a risk factor for 
alteration of bone mineral density in children as well as 
in adults.31–34 Imbalances in growth factors and cytokines, 
as well as the use of HAART could contribute to bone 
loss by increasing bone resorption. Previous studies have 
demonstrated adverse effects on bone metabolism by the 
administration of tenofovir in macaques, resulting primarily 
in decreased bone density.35–37 Infection of macaques by 
simian immunodeficiency virus was also implicated in 
affecting bone density. Histomorphometric analysis revealed 
in one of these studies an increase in tibial osteoid seam 
































Figure 1 Structures of tenofovir and tenofovir disoproxil fumarate (TDF).Therapeutics and Clinical Risk Management 2010:6 43
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into osteomalacia).35 The increase in osteoid seam width is 
likely associated with reduced activity in osteoblasts. Bone 
density reductions due to tenofovir have also been reported 
in human adults.38 Since tenofovir has a distinct and unique 
drug resistance profile, it satisfies the significant need for 
new non-cross-resistant HAART regimens in salvage therapy, 
particularly with children and adolescents. In light of this, off-
label clinical studies of tenofovir with HIV-infected children 
and adolescents have been conducted to investigate the 
efficacy of tenofovir-containing HAART regimens and to 
investigate whether tenofovir-associated bone loss is greater 
in children and adolescents than in adults.39–41 Increased 
bone resorption could cause a compensatory increase in 
osteoblast activity, which would be revealed by increased 
serum alkaline phosphatase levels.42 General conclusions 
drawn from these studies include that tenofovir treatment 
decreased bone mineral density as well as increased urinary 
calcium excretion. One limitation of these studies was the 
relatively small study size (ranging from 18 to 6 children). 
Another limitation of these studies is that the measurement of 
bone density is difficult in children and adolescents because 
of the dynamic yet variable rate of bone growth. Presently, 
there are different methods that are commonly used to mea-
sure bone density: dual-energy X-ray absorbtiometry (DXA), 
quantitative computed tomography (QCT), and quantitative 
ultrasound (QUS). Each approach has limitations and compar-
isons between these methods are difficult as comparative data 
analysis can be somewhat subjective. A study that analyzed 
the effect of TDF treatment of a group of 16 HIV-infected 
children and adolescents over a 1-year period concluded that 
TDF did not affect bone density when stavudine and protease 
inhibitor-containing regimens were compared with TDF/lami-
vudine/efavirenz.43 Differences in this study compared to that 
of the previously described studies include that the patients 
were older, had greater height and weight, and the majority 
were either in middle or late puberty or postpubertal. The 
children under study were also required to have long-lasting 
viral suppression prior to the switch to TDF and were exposed 
to TDF levels that may have been lower, as fractions of pills 
were administered. This study design is different to the other 
studies, which involved relatively younger children that did 
not have long lasting viral suppression prior to the switch to 
TDF, which were entire pills (ie, 300 mg).39–41
Mechanisms of tenofovir-associated 
bone loss
A significant literature exists on NRTIs that have implicated 
mitochondrial dysfunction, reviewed in.44–49 The inhibition of 
mitochondrial polymerase gamma could occur by competitive 
inhibition of polymerase gamma and/or the incorporation 
and subsequent DNA chain termination. The result would be 
a reduction in mitochondrial DNA synthesis. NRTIs could 
also indirectly inhibit DNA synthesis by inducing nucleo-
tide pool imbalances, oxidative stress, and DNA damage. 
Both direct and indirect mechanisms would result in the 
alteration of mitochondrial gene expression, which would 
cause mitochondrial dysfunction. NRTIs have greater affinity 
for affecting different tissue types as well as the nature of 
the mitochondrial-induced dysfunction in these tissue types, 
depending upon the NRTI. The analysis of NRTI-associated 
cellular stress has indicated that the mechanisms involved can 
be quite complex. NRTIs can result in altered gene expres-
sion profiles.50,51 Altered gene expression profiles have been 
observed in the absence of mitochondrial DNA depletion, 
suggesting that NRTIs can cause mitochondrial dysfunction 
and not inhibit mitochondrial DNA polymerase gamma.52
The association of tenofovir with mitochondrial dys-
function has been investigated. In general, no mitochondrial 
dysfunction was observed with tenofovir.53–56 Other studies 
have reported a lowering of mitochondrial dysfunction when 
drug regimens were changed and NRTIs were replaced with 
tenofovir.57–59 A recent study in rats found that very high doses 
(ie, 100 mg/kg/day) of tenofovir reduced mitochondrial DNA 
and gene expression in kidney cells.60 The relevance of this 
observation given the very high dosing used is unclear. In 
stark contrast, in an HIV transgenic mouse model tenofovir 
treatment was found to increase mitochondrial DNA content 
in kidney cells.61 Further analysis of mitochondrial DNA 
obtained from renal proximal tubules microdissected from 
kidney sections suggested that tenofovir lowered mitochon-
drial DNA levels in the renal proximal tubules.61 To date, no 
studies of mitochondrial dysfunction being associated with 
tenofovir-mediated bone loss have been reported. Overall, the 
current literature does not provide strong evidence for mito-
chondrial dysfunction being a major mechanism for tenfovir-
mediated cellular stress, particularly in regards to bone loss.
In vitro studies have previously reported that tenofovir 
diphosphate is a poor substrate and weak inhibitor of rat DNA 
polymerase alpha, delta and epsilon.55 Combined with the 
report of tenofovir diphosphate being poorly incorporated 
into DNA by the human mitochondrial DNA polymerase 
gamma,49 data are limited that would support a direct role 
of tenofovir in bone loss by the inhibition of either nuclear 
or mitochondrial DNA replication. While data are lack-
ing for tenofovir diphosphate being a good substrate for 
cellular DNA polymerases, the in vivo data correlating Therapeutics and Clinical Risk Management 2010:6 44
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tenofovir therapy with bone loss, particularly in children 
and adolescents who have very active and ongoing bone 
growth, implicate a role for tenofovir’s ability to impact 
cellular DNA synthesis. Such an impact could be either 
direct or indirect, such as 1) incorporation and DNA chain 
termination, 2) DNA damage, 3) alteration of deoxynucleo-
tide transport, and/or 4) nucleotide pool imbalances, which 
would perturb cellular DNA synthesis. The perturbation of 
cellular (ie, nuclear and/or mitochondrial) DNA synthesis 
would result in altered gene expression. The alteration of 
gene expression for genes involved in bone maintenance 
could explain the clinical observation of bone density loss 
during tenofovir treatment.
We propose three potential mechanisms for tenofovir-
associated bone loss. These include 1) preferential uptake by 
osteoclasts (altering gene expression and resulting in increased 
bone resorption), 2) update by osteoblasts (altering gene expres-
sion and decreasing bone formation), and 3) uptake by both 
osteoclasts and osteoblasts (altering gene expression of both 
cells types and ultimately the balance between bone resorp-
tion and bone formation – resulting in bone loss).
Since TDF is a phosphonate, it is possible that this could 
enhance its uptake into cells (Figure 2A), which would 
increase the probability of cellular stress. Bisphosphonates 
(ie, diphosphonates) are drugs used clinically to prevent loss 
of bone density, particularly in diseases such as osteoporosis, 
bone metastasis, multiple myeloma, Paget’s disease of bone, 
and primary hyperparathyroidism. Bisphosphonates target 
bone and inhibit osteoclast function after their cellular uptake 
by inducing apoptosis.62,63 Since tenofovir and TDF are both 
phosphonates, it is conceivable that they could also have an 
association with bone and be selectively taken up by osteo-
clasts by a mechanism similar to that of bisphosphonates, 
ultimately causing cellular stress. The resulting cellular stress 
would likely perturb cellular DNA synthesis (ie, nuclear 
and/or mitochondrial) and gene expression (Figure 2B). 
For example, the reduction of gene expression for an 
osteoclast gene that is involved in signaling osteoblast activity 
could ultimately result in a loss of bone density. It is formally 
possible that adjuvant treatment of bone density loss could 
improve the durability of tenofovir-containing HAART. 















Figure 2  The osteoclast as a target for   TDF.  A) Bone tissue, osteoblasts and osteoclasts. TDF, as a phosphonate, associates with bone tissue. Bone resorption by osteoclasts 
would result in the preferential uptake of   TDF.  B) Impact of  TDF on osteoclast DnA synthesis and gene expression. Following   TDF uptake by osteoclasts,   TDF can target the 
nucleus (1) and/or mitochondria (2), where it may directly or indirectly perturb DnA synthesis by 1) incorporation and DnA chain termination, 2) DnA damage, 3) alteration 
of deoxynucleotide transport, and/or 4) nucleotide pool imbalances.   The impact of  TDF on cellular DnA synthesis would result in altered gene expression (3).
Abbreviation: TDF, tenofovir disoproxil fumarate.Therapeutics and Clinical Risk Management 2010:6 45
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bisphosphonates could reduce bone density loss associated 
with tenofovir treatment.
The loss of bone density due to TDF exposure could also 
be associated with tenofovir-induced renal dysfunction – 
particularly renal proximal tubule dysfunction.42,61,64–72 The 
failure of renal proximal tubular cells to reabsorb filtered 
bicarbonate from the urine would result in urinary bicar-
bonate wasting and subsequent acidemia and a more 
general dysfunction of the proximal tubular cells – called 
Fanconi’s syndrome. Commonly observed conditions in 
Fanconi syndrome include aminoaciduria, glycosuria, tubular 
proteinuria, and uricosuria. Importantly, the main clinical 
feature of Fanconi’s syndrome is bone demineralization 
(osteomalacia or rickets) due to phosphate wasting. There-
fore, TDF-associated bone density loss may an outcome of 
renal dysfunction.
Summary
The distinctive resistance profile, high potency and limited 
side effects of tenofovir have made it an important component 
of HAART. The off-label use of tenofovir for treatment of 
children and adolescents is important for providing alterna-
tives to treatment-experienced patients. Also, tenofovir will 
likely play an important role in preventing mother-to-child 
transmission, particularly in the context of the appeal of 
TDF-containing fixed dose combinations in a single pill 
(ie, Atripla® and Truvada®). A concern in off-label tenofovir 
use is bone density loss. Current data indicate that tenofovir-
mediated bone loss is likely mediated by novel mechanisms 
not solely related to the known mitochondrial dysfunction 
associated with NRTIs. Future research will further aid in the 
elucidation the mechanism(s) involved in tenofovir-mediated 
bone loss, which would help in developing adjuvant therapies 
to reduce tenofovir-associated bone density loss.
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